Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26201180 | 0.75 | ELANE (0.35) | ELANENPC1POLBGAANPSR1 | |
| SCHEMBL17414527 | 0.75 | ELANE (0.33) | ELANENPC1 | |
| SCHEMBL17388254 | 0.75 | ELANE (0.33) | ELANENPC1 | |
| SCHEMBL821494 | 0.75 | ELANE (0.33) | ELANENPC1 | |
| SCHEMBL14562352 | 0.75 | ELANE (0.33) | ELANENPC1 | |
| SCHEMBL31320358 | 0.75 | ELANE (0.33) | ELANENPC1 | |
| SCHEMBL26201175 | 0.74 | NPC1 (0.33) | ELANENPC1POLBGAANPSR1 | |
| SCHEMBL27026217 | 0.74 | CNR2 (0.38) | ELANE | |
| SCHEMBL26201589 | 0.70 | ELANE (0.33) | ELANENPC1POLBGAANPSR1 | |
| SCHEMBL26201200 | 0.69 | CNR2 (0.33) | ELANENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | CYP3A43, PRMT8, MGMT | ELANE 1084/4885NPC1 3226/4885POLB 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.